BP during laryngoscopy (may result in transient hypotension).

• Requires intraarterial BP monitoring and use of infusion pump.

• Must be protected from light because of photodegradation.

Sodium Nitroprusside: Metabolism Key Points

• Thiocyanate is slowly cleared by the kidneys. In patients with renal failure, accumulation of large amounts of thiocyanate may result in thyroid dysfunction, muscle weakness, nausea, hypoxia, and acute toxic psychosis.

• The last of the three cyanide reactions is responsible for the development of acute cyanide toxicity, which is characterized by metabolic acidosis, cardiac arrhythmias, and increased venous oxygen content (inability to utilize oxygen).

• Another early sign of cyanide toxicity is the acute resistance to the hypotensive effects of escalating doses of sodium nitroprusside (tachyphylaxis).

• Cyanide toxicity can usually be avoided if cumulative dose of sodium nitroprusside is less than 0.5 mg/kg/h.

• Pharmacologic treatment of cyanide toxicity: Aim to shunt cyanide away from cytochrome oxidase.

• Methemoglobinemia from excessive doses of sodium nitroprusside or sodium nitrate can be treated with methylene blue (1–2 mg/kg of a 1% solution over 5 min); reduces methemoglobin to hemoglobin.

Sodium Nitroprusside: Effect on Organ Systems

• Combined dilation of venous and arteriolar vascular beds = preload and afterload = BP.

Cardiac: Cardiac output is generally unchanged in normal patients.

• Cardiac output is increased in patients with congestive heart failure (CHF), mitral regurgitation, and aortic regurgitation secondary to afterload.

• Preload, myocardial work, and therefore likelihood of ischemia.

• Reflex-mediated tachycardia and contractility (offset the favorable changes in myocardial oxygen requirements).

• Dilation of coronary arterioles by sodium nitroprusside may result in an intracoronary steal of blood away from ischemic areas that are already maximally dilated.

Cerebral: Dilates cerebral blood vessels and abolishes cerebral autoregulation.

• Cerebral blood flow (CBF) is maintained (or increased) unless BP is markedly reduced.

• Increased cerebral blood volume leads to increased intracranial pressure (ICP), particularly in patients with reduced intracranial compliance (e.g., brain tumor).

• Intracranial hypertension may be minimized by slow administration and hyperventilation or hypocapnia.

Pulmonary: Vasculature dilates.

• Reductions in pulmonary artery pressure decrease perfusion to normally ventilated alveoli, thereby physiologic dead space = V/Q mismatch and arterial oxygenation.

• Inhibits hypoxic pulmonary vasoconstriction: V/Q mismatch and arterial oxygenation.

Renal: Renin and catecholamines are released in response to BP

Notable Drug Interactions

• Neuromuscular blockade: May indirectly delay the onset and prolong the duration of blockade by decreasing muscle blood flow secondary to arterial hypotension

Nitroglycerin: Mechanism of Action

• Same as sodium nitroprusside; relaxes vascular smooth muscle through NO pathway, with venous dilation predominating over arterial dilation

Clinical uses: Relieves myocardial ischemia, hypertension, and ventricular failure

• Commonly diluted to a concentration of 100 μg/mL

• Administered as a continuous IV infusion: 0.5 to 10 μg/kg/min

• Glass containers and special IV tubing are recommended because of adsorption of nitroglycerin to polyvinylchloride

• May also be administered by a sublingual (peak effect, 4 min) or transdermal (sustained release for 24 h) route

• Chronic use may result in tolerance: may be due to depletion of reactants necessary for NO formation, compensatory increase in vasoconstrictive substances, or volume expansion

Related posts:

Intravenous Anesthetics Anesthesia for Patients with Cardiovascular Disease Anesthesia for Genitourinary Surgery Ambulatory, Non–Operating Room, and Office-Based Anesthesia Spinal, Epidural, and Caudal Blocks Cholinesterase Inhibitors and Other Pharmacologic Antagonists to Neuromuscular Blocking Agents